Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System

Fresenius Kabi announced today it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.

“We deeply appreciate this vote of confidence in the Ivenix Infusion System and look forward to working with Premier members,” said Christian Hauer, executive board member and president, Fresenius Kabi MedTech. “Health systems and their nursing teams face many day-to-day challenges associated with infusion therapy. The Ivenix Infusion System is designed to improve the simplicity, intelligence and reliability of infusion pumps. We’re pleased Premier chose to make our smart infusion system available to its members.”

The Ivenix Infusion System is designed to overcome deficiencies in legacy pumps. The Ivenix patented pumping technology delivers critical medications with flow that is measured and controlled to help optimize safety. The pump operates unaffected by external conditions such as bag height, back pressure, and fluid viscosity to deliver accurate medication delivery, and it protects patients from uncontrolled flow.

The Ivenix Large-Volume Pump includes a large, smartphone-like touchscreen that allows clinicians to auto-program, review, and accept medication orders on the pump. The built-in integration engine within the Ivenix Infusion System supports secure interoperability with leading electronic medical records (EMR) systems. The Ivenix system from Fresenius Kabi also offers valuable tools to automate testing, reducing the implementation timeline and the resources needed to synchronize the drug library with the EMR formulary.

The Ivenix platform also facilitates enterprise-wide, centralized management of the entire pump fleet. This device command center allows for comprehensive oversight of the infusion pump fleet from device utilization to location awareness, proactive maintenance, user management, and remote software and security updates—without wasting valuable time hunting and gathering devices.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”